Proshares UltraPro NASDAQ Biotechnology
UBIO
UBIO was delisted on the 27th of March, 2020.
6 hedge funds and large institutions have $1.25M invested in Proshares UltraPro NASDAQ Biotechnology in 2018 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 4 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
14% less funds holding
Funds holding: 7 → 6 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
53% less call options, than puts
Call options by funds: $239K | Put options by funds: $506K
63% less capital invested
Capital invested by funds: $3.4M → $1.25M (-$2.15M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$832K |
| 2 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$26.5K |
| 3 |
Morgan Stanley
New York
|
+$22.3K |
| 4 |
AIM
Anchor Investment Management
Columbia,
South Carolina
|
+$10.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.28M |
| 2 |
ACM
Avalon Capital Management
Port Of Redwood City,
California
|
-$818K |
| 3 |
Jane Street
New York
|
-$576K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$179K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$101K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
1
Virtu Financial
New York
| $721K | +$832K | +22,644 | New |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $459K | -$179K | -4,865 | -25% |
|
|
3
Morgan Stanley
New York
| $29K | +$22.3K | +606 | +202% |
|
|
LTFS
4
Ladenburg Thalmann Financial Services
Miami,
Florida
| $23K | +$26.5K | +720 | New |
|
|
CG
5
Cutler Group
San Francisco,
California
| $12K | – | – | – |
|
|
AIM
6
Anchor Investment Management
Columbia,
South Carolina
| $8.75K | +$10.1K | +275 | New |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| – | -$1.28M | -38,065 | Closed |
|
|
ACM
8
Avalon Capital Management
Port Of Redwood City,
California
| – | -$818K | -24,329 | Closed |
|
|
9
Jane Street
New York
| – | -$576K | -15,656 | Closed |
|
|
10
UBS Group
Zurich,
Switzerland
| – | -$101K | -3,003 | Closed |
|
UBIO Hedge Fund Activity: Q1 2018 in Review
6 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Proshares UltraPro NASDAQ Biotechnology (UBIO) for Q1 2018, worth a combined $1.25M — down 63% from $3.4M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of UBIO and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was Virtu Financial, opening a new position worth an estimated $832K. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $1.28M sold.
- 6 institutional investors held Proshares UltraPro NASDAQ Biotechnology (UBIO) as of Q1 2018, down from 7 in Q4 2017.
- Funds reported $1.25M of Proshares UltraPro NASDAQ Biotechnology stock for Q1 2018, down 63% quarter-over-quarter.
- 3 funds opened new Proshares UltraPro NASDAQ Biotechnology positions in Q1 2018 and 4 closed out, a net change of -1 holder.
- The largest Proshares UltraPro NASDAQ Biotechnology buyer in Q1 2018 was Virtu Financial, an estimated $832K added.
- The largest Proshares UltraPro NASDAQ Biotechnology seller in Q1 2018 was Tower Research Capital (TRC), an estimated $1.28M sold.
Based on aggregated 13F filings for Q1 2018.